Alnylam Pharmaceuticals | ALNY - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amgen USD 6.89B 415M 2025-12
Arrowhead Research USD 264.03M 7.56M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Incyte USD 1.17B 217.51M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
Moderna USD -566M 792M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 10.82B 694M 2025-09
PTC Therapeutics USD 232.94M 84.56M 2026-03
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 3.02B 2025-12
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Takeda JPY 688.84B 101.71B 2026-03
Tectonic Therapeutic USD 0 0 2025-03
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03
Xencor USD 21M 22.61M 2025-09